openPR Logo
Press release

NOACs Pricing, Reimbursement, and Access

08-08-2017 08:39 AM CET | Health & Medicine

Press release from: ReportsWorldwide

ReportsWorldwide has announced the addition of a new report title NOACs Pricing, Reimbursement, and Access to its growing collection of premium market research reports.

A combination of the high cost of novel oral anticoagulants (NOACs) (relative to highly genericized vitamin K antagonists) and the large patient populations these drugs address, has resulted in this class of compounds being a top priority for European payers. The impact of NOACs on European budgets is so great that a UK payer stated that this represented their single largest budgetary concern over the past year. However, in the US, payers were not as concerned with the budgetary impact of the NOACs, citing that this falls outside of their top 20 budgetary concerns. Additionally, most interviewed US payer view NOACs as the new standard of care due to their reduction of serious bleeding events and hence cost saving as compared to vitamin K antagonists.

For a Detailed description and table of contents of this report please click here: https://www.reportsworldwide.com/report/noacs-pricing-reimbursement-and-access

Payers interviewed by Datamonitor Healthcare generally view the marketed NOAC compounds as highly similar, acknowledging that while there are some minor differences in the clinical data of these compounds, the rate of events in their trials is so low that it is hard to attribute these differences to the medications. Moving forward, payers view patients with poor renal function as an area of high unmet need.

Payers interviewed discussed how they would welcome a simple dosing regimen that would not need to be modified for patients with poor renal function; this “one size fits all” dosing regimen would simplify the prescribing of physicians and ensure that all of the patients received the correct dose regardless of their renal function.

However, payers cautioned that it is unlikely that improvements in treatment with respect to efficacy and safety can be achieved given the opposing coagulation and anticoagulation processes in the body. They also stress the importance of delivering game-changing improvements and emphasize that a new agent with the same mechanism of action would be unlikely to capture market share or even be reimbursed unless it targeted specific subpopulations that are currently underserved.

Opinions around the clinical attractiveness of betrixaban (pipeline medication in development for prophylaxis of venous thromboembolism) were split, with some viewing the results from the APEX trial as clinically relevant while others did not feel the medication provided benefit.

To Get Sample Copy of Report please visit @ https://www.reportsworldwide.com/enquiry?report_id=41338

About ReportsWorldwide.com

ReportsWorldwide.com is a leading provider of global market intelligence reports and services. With research reports from top publishers, consulting and advisory firms, ReportsWorldwide.com offers instant online access to a growing database of expert insights on global industries, companies, products, geographies and trends.

Press Contact:
Abigail Crasto
Senior Vice President
101, Arch Street
Boston, MA 02110
US
Phone +1 (617) 398-4994
Fax +1 (617) 398-4995
abigail@reportsworldwide.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release NOACs Pricing, Reimbursement, and Access here

News-ID: 658655 • Views: 285

More Releases from ReportsWorldwide

World Deep Brain Stimulation Market Top Segments, Key Players Revenue, Growth Ra …
The World Deep Brain Stimulation Market is estimated to represent a global market of USD 751.8 million by 2017 with growth rate of 18.2%. Deep brain stimulation (DBS) procedure is primarily used for the treatment of neuropsychiatric disorders such as mood disorder, dementia, anxiety and others. The procedure involve the use of neurotransmitter (brain pacemaker) that enables to transmit electric impulses to the specific target of brain cells. Increasing incidence
New report explores the Gene Editing Market : Ushering The Next Breakthrough in …
Boston, MA ReportsWorldwide has announced the addition of a new report title Gene Editing The Next Breakthrough in Regenerative Medicine to its growing collection of premium market research reports. Genome editing is a type of genetic engineering in which DNA is replaced, inserted or deleted in a living organism's ggenome using engineered molecular scissors. Believed to be one of the great biotechnology breakthroughs, gene editing is a powerful tool in pharmaceutical research that
Global In-Building Wireless BTSController-based Small Cells Market Analysis and …
Boston, MA ReportsWorldwide has announced the addition of a new report title Global In-Building Wireless BTSController-based Small Cells Market Analysis and Forecast, 2017-2021 to its growing collection of premium market research reports. This report covers the leading in-building wireless enterprise BTS/controller-based small cells network equipment manufacturers: • CommScope/Airvana • Comba Telecom • Ericsson • Huawei Technologies • Nokia • SpiderCloud • ZTE Corporation This report covers the global market share for 2016 shipments as well as a forecast for 2017-2021. To view a detailed description and Table of
UDAY’s Impact and Compatibility State wise indexing of Integrated Power Supply …
Boston, MA ReportsWorldwide has announced the addition of a new report title UDAY’s Impact and Compatibility State wise indexing of Integrated Power Supply Chain in India – 2017 to its growing collection of premium market research reports. UDAY scheme was touted as the next paladin to bail out the struggling Discoms, in order to turn them green in a time horizon of 3-4 years from 2015/16. Though was optional for the

All 5 Releases


More Releases for NOAC

Novel Oral AntiCoagulants (NOAC) Market 2020 | Strategic Assessment by Top Playe …
The Global Novel Oral AntiCoagulants (NOAC) Market research report provides and in-depth analysis on industry- and economy-wide database for business management that could potentially offer development and profitability for players in this market. It offers critical information pertaining to the current and future growth of the market. It focuses on technologies, volume, and materials in, and in-depth analysis of the market. The study has a section dedicated for profiling key
Anticoagulants Market Latest Innovations by Leading Key Players like Bayer Healt …
Anticoagulants Market – Overview Anticoagulants prevent clot formation or enlargement of existing clots in the arteries or veins. Heparins, including unfractionated heparin (UFH) and low molecular weight heparin (LMWH); vitamin K antagonists, DTIs, and factor Xa inhibitors, are the various anticoagulants available in the market. These are used for indications such as heart attack, stroke, deep venous thrombosis (DVT), pulmonary embolism (PE), surgery, angina, dialysis, atrial fibrillation (AF), thrombocytopenia, and myocardial
Novel Oral AntiCoagulants (NOAC) Market to Escalate by Types, Applications, Regi …
This report at InForGrowth studies the global market size of Novel Oral AntiCoagulants (NOAC) in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Novel Oral AntiCoagulants (NOAC) in these regions. This research report categorizes the global Novel Oral AntiCoagulants (NOAC) market by players/brands, region, type and application. This report also studies the global market status, competition
Novel Oral AntiCoagulants (NOAC) Market 2018 SWOT Analysis by Players: Johnson & …
The Global Novel Oral AntiCoagulants (NOAC) Market 2018 to 2025 renders deep perception of the key regional market status of the Novel Oral AntiCoagulants (NOAC) Industry on a global level that primarily aims the core regions which comprises of continents like Europe, North America, and Asia and the key countries such as United States, Germany, China and Japan. The report on “Global Novel Oral AntiCoagulants (NOAC) Market” is a professional report
Europe Novel Oral AntiCoagulants (NOAC) Market Analysis- Size, Share, Growth, In …
QY Research Groups has published its new and latest market report based on thorough research on the Novel Oral AntiCoagulants (NOAC) Market. This detailed, all-inclusive report renders an integrated approach to growth of the market along with an elaborate and accurate analysis of the complete competitive situation of this market on a Europe level with the key market trends and newest technologies, being a major part in the market’s growth
Global Novel Oral AntiCoagulants (NOAC) Market Research Report 2016
Qyresearchreports include new market research report “Global Novel Oral AntiCoagulants (NOAC) Market Research Report 2016″ to its huge collection of research reports. The analysts of the global Novel Oral AntiCoagulants (NOAC) market report have taken on the challenge of procuring insightful data from reliable resources and precisely segregating critical market dynamics, given the voluminous amount of information available. Established and novice players in the Novel Oral AntiCoagulants (NOAC) market can secure